{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:05:28Z","timestamp":1791291928870,"version":"4.1.0"},"reference-count":26,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2015,2,3]],"date-time":"2015-02-03T00:00:00Z","timestamp":1422921600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["PrionSecur ANRPRIB02302"],"award-info":[{"award-number":["PrionSecur ANRPRIB02302"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2015,6]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Analysis of archived appendix samples reveals that one in 2000 individuals in the United Kingdom may carry the infectious prion protein associated with variant Creutzfeldt\u2010Jakob disease (vCJD), raising questions about the risk of transfusion transmission from apparently healthy carriers. Blood leukoreduction shows limited efficiency against prions. Therefore, in absence of antemortem diagnostic tests, prion removal filters, including the P\u2010Capt filter were designed to improve blood transfusion safety.<\/jats:p><\/jats:sec><jats:sec><jats:title>STUDY DESIGN AND METHODS<\/jats:title><jats:p>We evaluated the performances of two filters, the P\u2010Capt and one prototype (PMC#005), with blood\u2010borne infectivity in two independent experiments. Blood was drawn twice from prion\u2010infected macaques. Corresponding RBCCs were prepared according to two different procedures: in Study\u00a0A, the leukoreduction step was followed by the filtration through the P\u2010Capt. In Study\u00a0B, the leukoreduction and prion removal were performed simultaneously through the PMC#005. For each study, two groups of three animals were transfused twice with samples before or after filtration.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Among the six macaques transfused with nonfiltered samples, five developed neurologic signs but only four exhibited peripheral detectable protease\u2010resistant prion protein (PrPres) accumulation. In Study\u00a0A, the three animals transfused with P\u2010Capt\u2013filtered samples remain asymptomatic and devoid of PrPres in lymph node biopsies 6\u00a0years after the transfusion. In Study\u00a0B, one animal transfused with PMC#005\u2010filtered samples developed vCJD.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p>After 5 to 6 years of progress, this ongoing study provides encouraging results on the prion blood removal performances of the P\u2010Capt filter in macaques, an utmost relevant model for human prion diseases.<\/jats:p><\/jats:sec>","DOI":"10.1111\/trf.12999","type":"journal-article","created":{"date-parts":[[2015,2,3]],"date-time":"2015-02-03T13:35:33Z","timestamp":1422970533000},"page":"1231-1241","source":"Crossref","is-referenced-by-count":16,"title":["Evaluation of the protection of primates transfused with variant Creutzfeldt\u2010Jakob disease\u2013infected blood products filtered with prion removal devices: a 5\u2010year update"],"prefix":"10.1111","volume":"55","author":[{"given":"Nathalie","family":"Lescoutra\u2010Etchegaray","sequence":"first","affiliation":[{"name":"Macopharma Fontenay\u2010aux\u2010Roses France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Jaffr\u00e9","sequence":"additional","affiliation":[{"name":"Macopharma Fontenay\u2010aux\u2010Roses France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chryslain","family":"Sumian","sequence":"additional","affiliation":[{"name":"Macopharma Tourcoing France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Durand","sequence":"additional","affiliation":[{"name":"Division of Prions and Related Diseases (SEPIA) CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI) Fontenay\u2010aux\u2010Roses France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyne","family":"Correia","sequence":"additional","affiliation":[{"name":"Division of Prions and Related Diseases (SEPIA) CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI) Fontenay\u2010aux\u2010Roses France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Mikol","sequence":"additional","affiliation":[{"name":"Division of Prions and Related Diseases (SEPIA) CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI) Fontenay\u2010aux\u2010Roses France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Luccantoni\u2010Freire","sequence":"additional","affiliation":[{"name":"Division of Prions and Related Diseases (SEPIA) CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI) Fontenay\u2010aux\u2010Roses France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Culeux","sequence":"additional","affiliation":[{"name":"Macopharma Fontenay\u2010aux\u2010Roses France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Philippe","family":"Deslys","sequence":"additional","affiliation":[{"name":"Division of Prions and Related Diseases (SEPIA) CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI) Fontenay\u2010aux\u2010Roses France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel E.","family":"Comoy","sequence":"additional","affiliation":[{"name":"Division of Prions and Related Diseases (SEPIA) CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI) Fontenay\u2010aux\u2010Roses France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,2,3]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/bmb\/66.1.255"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15486-X"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2006.00837.x"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2009.01222.x"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f5675"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/382779a0"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/bmb\/66.1.185"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16812-8"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12369"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02525.x"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69897-8"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2006.00865.x"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12420"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12188"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03133.x"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2010.01330.x"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3148.2009.00918.x"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.22.14339-14345.2005"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15487-1"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003017"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/381743a0"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.041490898"},{"key":"e_1_2_8_24_1","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0140-6736(05)17985-9","article-title":"Risk of oral infection with bovine spongiform encephalopathy agent in primates","volume":"365","author":"Lasm\u00e9zas CI","year":"2005","journal-title":"Lancet"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2013.5378"},{"key":"e_1_2_8_26_1","unstructured":"National CJD Research & Surveillance Unit University of Edinburgh. Creutzfeldt\u2010Jakob disease in the UK (by calendar year). Edinburgh: The University of Edinburgh; 2014 [cited 2014 Oct 27]. Available from:http:\/\/www.cjd.ed.ac.uk\/documents\/figs.pdf."},{"key":"e_1_2_8_27_1","unstructured":"Institut de Veille Sanitaire (INVS). CJD\u2014number of cases in France. Saint\u2010Maurice: INVS France; 2014 [cited 2014 Oct 27]. Available from:http:\/\/www.invs.sante.fr\/Dossiers-thematiques\/Maladies-infectieuses\/Risques-infectieux-d-origine-alimentaire\/Maladie-de-Creutzfeldt-Jakob\/Donnees-epidemiologiques."}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftrf.12999","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.12999","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T20:00:25Z","timestamp":1695499225000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.12999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,3]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["10.1111\/trf.12999"],"URL":"https:\/\/doi.org\/10.1111\/trf.12999","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,3]]}}}